Skip to main content
  • Poster presentation
  • Open access
  • Published:

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison


To intra-individually compare 0.1 and 0.05 mmol/kg gadobenate (MultiHance) with 0.1 mmol/kg gadoterate (Dotarem) for contrast-enhanced MRI of brain tumours.

Method and materials

One hundred seventy-seven adult patients with suspected or known brain tumours were randomised to one of two study arms to undergo two identical exams at 1.5T, one with gadobenate at 0.1 (Arm 1; 70 patients) or 0.05 (Arm 2; 107 patients) mmol/kg bodyweight, and the other with gadoterate at 0.1 mmol/kg bodyweight. The agents were injected in randomised order separated by 2–14 days. Imaging sequences (T1SE and T1GRE) and acquisition timing were identical for the two exams. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for % lesion enhancement and lesion-to-background ratio (LBR). Safety assessments were performed.


In Arm 1, readers 1, 2 and 3 demonstrated highly significant global preference for gadobenate (31 vs. 1, 51 vs. 2, 43 vs. 2 patients, respectively; p<0.0001, all readers), all other qualitative endpoints (p≤0.0023; all readers) and for % enhancement (p≤0.0006) and LBR (p<0.0001). Significant (p=0.023) differences between 0.05 mmol/kg gadobenate and 0.1 mmol/kg gadoterate (in favour of gadobenate) were noted only by reader 2 for % enhancement. Study agent related adverse events were reported by 2/169 (1.2%) patients after gadobenate and by 5/175 (2.9%) patients after gadoterate.


Significantly superior morphologic information and contrast enhancement are demonstrated on brain MRI with 0.1 mmol/kg gadobenate compared to 0.1 mmol/kg gadoterate. No meaningful differences were recorded between 0.05 mmol/kg gadobenate and 0.1 mmol/kg gadoterate.

Author information

Authors and Affiliations


Corresponding author

Correspondence to MA Kirchin.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaneckova, M., Herman, M., Smith, M. et al. Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison. Cancer Imaging 15 (Suppl 1), P15 (2015).

Download citation

  • Published:

  • DOI: